We focus on the development of a wide variety of therapeutic monoclonal antibody products that provide medically differentiated therapies in cancers and the treatment of autoimmune diseases, which, according to Frost & Sullivan, are among the largest therapeutic areas in the monoclonal antibody segment, with an aggregate market size of RMB10.4 billion in 2017 and an expected aggregate market size of RMB64.6 billion in 2022.

Within our product pipeline, we currently have three Core Products under the phase III clinical development and two other products approved for clinical trial.

CMAB007 (omalizumab) is our new humanized monoclonal antibody drug candidate. It is the only mAb asthma therapy developed in China by a local Chinese company that has reached phase III clinical trial. In addition, clinical trials for our other Core Products CMAB008 and CMAB009 have shown comparative curative effect as, and clear advantages in terms of adverse effects over, similar marketed products based on their published clinical results. We expect to submit NDAs for CMAB007, CMAB009 and CMAB008 in 2020, 2021 and 2019, respectively.